OncoMed Pharmaceuticals, Inc. (NASDAQ: OMED) announced dosing of the first patient in a Phase 1b clinical trial of anti-DLL4/VEGF bispecific ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE